Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta–treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.
FerrajoliAO’BrienSMCortesJE. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer2003; 98(4): 773–778.
2.
MoretonPKennedyBLucasG. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol2005; 23(13): 2971–2979.
3.
HartungHPAktasOBoykoAN.Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult Scler2015; 21(1): 22–34.
4.
RaiKRFreterCEMercierRJ. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol2002; 20(18): 3891–3897.
5.
CohenJAColesAJArnoldDL.; CARE-MS I Investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1819–1828.
6.
ColesAJTwymanCLArnoldDL.; CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1829–1839.
7.
O’BrienSMKeatingMJMocarskiES.Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma2006; 7(2): 125–130.
8.
WraySArnoldDLCohenJ. Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. In: Presented as poster at the annual meeting of the consortium for multiple sclerosis centers, Orlando, FL, 29 May–1 June 2013.
9.
WillisMDRobertsonNP.Alemtuzumab for multiple sclerosis. Curr Neurol Neurosci Rep2016; 16: 84.
10.
FaderlSCoutréSByrdJC. The evolving role of alemtuzumab in management of patients with CLL. Leukemia2005; 19(12): 2147–2152.
